About the Human Integrative Physiology laboratory
The Human Integrative Physiology (HIP) laboratory is focused on enhancing the prevention and treatment of cardiometabolic diseases in at-risk groups. We use innovative, multidisciplinary approaches to enhance our understanding of cardiometabolic diseases, especially those that are characterised by exercise intolerance. To better understand exercise intolerance, our lab uses state-of-the-art imaging-based approaches (MRI, echocardiography and vascular ultrasound), classic invasive hemodynamic monitoring techniques, cardiopulmonary exercise testing, big data and bioinformatics and other novel techniques.
Our team are international leaders in the field of 'exercise medicine'. We develop individualised, targeted exercise program to prevent and treat cardiometabolic dysfunction. The HIP lab conducts rigorous, randomised clinical trials in a range of clinical populations to test the benefits of these interventions. The group has a particular interest in the role of 'exercise medicine' for oncology patients (breast and haematology cancers) and patients at risk of heart failure. We are evaluating the efficacy of interventions via both patient-related and physiological outcomes and have a particular focus on understanding the mechanisms that are associated with cardioprotective effects of exercise.
We collaborate extensively with national and international leaders in the fields of cardiology, exercise and integrative physiology. At the Baker Institute, we work closely with the Sports Cardiology laboratory.